Trial Profile
A Multi-Center, Open-Label, First-in-Human, Phase I Dose-Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO6839921, An MDM2 Antagonist, Following Intravenous Administration in Patients With Advanced Malignancies, Including Acute Myeloid Leukemia (AML)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs RG 7775 (Primary)
- Indications Acute myeloid leukaemia; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Roche
- 04 Feb 2020 Results of Phase 1 study of the RO6839921 in patients with acute myeloid leukemia has been published in the Investigational New Drugs
- 16 Nov 2019 Results assessing safety, PK and PD of RO6839921 in patients with advanced solid tumors published in the Investigational New Drugs
- 16 May 2018 Status changed from active, no longer recruiting to completed.